



# Closing the Care Gap: Oviva Secures €200 Million to Expand AI-Enabled Healthcare Across Europe

*Europe's leading digital health platform closes Series D round to expand access to chronic care, led by long-term, impact-focused healthcare investors.*

**Berlin, January 22, 2026** – [Oviva](#), a leading European provider of digital, reimbursed care for weight-related and chronic conditions, has secured €200 million in a Series D financing round. The round is led by [Kinnevik](#), who has a track record of backing category winners in digital health, with participation from [Planet First Partners](#), [A.P. Moller Holding](#), [Lunate](#), [EGS Beteiligungen AG](#), and [Norrsken VC](#), alongside continued support from existing investor [Sofina](#).



Oviva founder team: Kai Eberhardt, CEO, and Manuel Baumann, CTO © Anastasia Chernykh

The round will support rising demand for reimbursed digital healthcare and help expand into chronic indications, including hypertension and type 2 diabetes, to help prevent and manage costly comorbidities. The company will also advance its AI-powered tools to better support patients and clinicians.

## Addressing a Growing Healthcare Gap

Across Europe, more than 200 million adults live with obesity and related chronic conditions, while access to effective, long-term healthcare remains limited. Health systems face rising demand from chronic conditions, shortages of specialised clinicians, long waiting times for structured care programmes, and delivery models that rely heavily on in-person care and therefore struggle to meet the demand.

Oviva was built to close this gap. The company's certified digital therapy programmes are fully reimbursed by statutory health insurers and national health systems in Germany, Switzerland and the UK. Accredited digital healthcare applications and programmes from Oviva provide patients with access to structured, multidisciplinary care without long delays and independent of location.



**Kai Eberhardt**, CEO and Co-Founder of Oviva © Anastasia Chernykh

"This investment allows us to do what we set out to do: make effective care accessible to everyone who needs it," said **Kai Eberhardt, CEO and Co-Founder of Oviva**. "By intervening earlier and supporting patients continuously over time, we help prevent disease progression, free up clinical capacity, and enable healthcare systems to deliver better outcomes with limited resources."

To date, the company has supported more than one million people in improving their health through evidence-based lifestyle and behavioural interventions – a European milestone for digital healthcare. More than 90 peer-reviewed abstracts and publications document the

clinical evidence underpinning Oviva's programmes and demonstrate sustained outcomes across large patient populations.

## AI as an Enabler for Personalised Healthcare at Scale

Oviva's platform combines a medical-device-certified app with access to multidisciplinary care teams. AI is embedded across the platform to enable personalised treatment pathways, support clinicians in their day-to-day work and ensure high-quality delivery at scale – helping address workforce shortages while improving the patient experience, without compromising clinical standards.



Christian Scherrer, Senior Investment Director at Kinnevik © Kinnevik

"Oviva has demonstrated that digital care can deliver measurable health outcomes at scale. By addressing some of the most pressing and costly conditions, we believe the company is already transforming health economics for the heavily strained European healthcare systems", said **Christian Scherrer, Senior Investment Director at Kinnevik**. "We see significant potential to expand this model across conditions and geographies and empower Oviva to provide critical infrastructure that European health systems urgently need."

## Engagement langfristig orientierter Healthcare-Investoren mit Impact-Fokus

This investment brings together a group of long-term, impact-focused healthcare investors aligned with Oviva's mission to improve access to effective chronic care at scale.

Founded in 2014, Oviva has expanded its operations across markets, reached cash-flow profitability in 2025 and tripled new patient intake over the past two years, underscoring the sustainability of its reimbursed care model.

## **About Oviva**

Founded in 2014 by Kai Eberhardt and Manuel Baumann, Oviva is Europe's leading provider of digital, reimbursed care for weight-related and chronic conditions. Its AI-enabled platform combines a medical-device-certified app with multidisciplinary clinical teams to deliver personalised, evidence-based therapy at scale.

Oviva works closely with public health systems, insurers and clinicians. Its programmes are reimbursed across all core markets: as a certified Digital Health Application (DiGA) in Germany, in partnership with the NHS in the UK, and as an integrated part of the Swiss healthcare system.

Oviva's approach is clinically validated, outcome-driven and designed to reduce the burden on healthcare professionals while improving access, quality and efficiency of care. In 2026, Oviva expanded its platform to include hypertension management, further strengthening its role as a comprehensive digital chronic care provider.

For more information, visit: [www.oviva.com](http://www.oviva.com)

## **About Kinnevik**

Kinnevik is a leading growth investor on a mission to redefine industries and create remarkable growth companies. As an active owner and operational partner, Kinnevik provides patient capital to challenger technology-enabled businesses in Europe and the US. Our passionate founders are building tomorrow's leaders within healthcare, software and climate, making everyday life easier and better for people around the world. Kinnevik was founded in 1936 by the Stenbeck, Klingspor and von Horn families. Kinnevik's shares are listed on Nasdaq Stockholm.

## **Transaction Advisors**

Lazard acted as exclusive financial advisor to Oviva in connection with the Series D financing round.